Dual Target Molecular Imaging in precision management of breast cancer: The time has come

Main Article Content

Partha Choudhury Manoj Gupta

Abstract

No abstract as it is an editorial commentary

Article Details

How to Cite
CHOUDHURY, Partha; GUPTA, Manoj. Dual Target Molecular Imaging in precision management of breast cancer: The time has come. Medical Research Archives, [S.l.], v. 5, n. Issue 9, sep. 2017. ISSN 2375-1924. Available at: <http://journals.ke-i.org/index.php/mra/article/view/1489>. Date accessed: 17 oct. 2017.
Keywords
Breast Cancer, Estrogen Receptor, FES imaging
Section
Review Articles

References

References:
1. Fisher B,Costantino J, Redmond C, Poisson R, Bowman D et al. A randomized clinical trial evaluating Tamoxifen in the treatment of patients with node negative breast cancer who have estrogen receptor positive tumors. N. Engl J Med 1989;320 : 479-84

2. Ellis Mathew J, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janike F. Letrozole is more effective neoadjuvant endocrine therapy than Tamoxifen for ErbB-1 and/or ErbB2-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19 Sept 2001; (18) 3808-16.

3. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W et al. Gene expression and benefit of chemotherapy in women with node negative, estrogen receptor positive breast cancer. J. Clin Oncol; 24 Aug 2006 (23) : 3726-34

4. Stacey SN, Manolescu A, Sulem P, Thorlacius S, Gudjonsson SA, Jonsson GF et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor –positive breast cancer. Nature Genetics 2008; 40 : 703-06.

5. Ulaner GA, Castillo R, Goldman DA, Wills J, Riedl CC et al. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple negative breast cancer. Eur J Nucl Med Mol Imaging. 2016; 43(11) : 1937-44

6. Riedl CC, Pinker K, Ulaner GA, Ong LT, Baltzer P, Jochelson MS et al. Comparison of FDG PET/CT and contrast enhanced CT for monitoring therapy response in patients with metastatic breast cancer. Eur J Nucl Med Mol Imaging 2017; 44(9) : 1428-37

7. Rosen EL, Eubank WB, Mankoff DA. 18F‑FDG PET, PET/CT, and breast cancer imaging. Radiographics 2007;27 Suppl 1:S215‑29.

8. Groheux D, Espié M, Giacchetti S, Hindié E. Performance of 18F‑FDG PET/CT in the clinical management of breast cancer. Radiology 2013;266:388‑405.

9. Manohar K, Mittal BR, Senthil R, Kashyap R, Bhattacharya A, Singh G. Clinical utility of F‑18 18F‑FDG PET/CT in recurrent breast carcinoma. Nucl Med Commun 2012;33:591‑6.

10. Eubank WB. Diagnosis of recurrent and metastatic disease using f‑18 fluorodeoxyglucose‑positron emission tomography in breast cancer. Radiol Clin North Am 2007;45:659‑67.

11. Isasi CR, Moadel RM, Blaufox MD. A meta‑analysis of 18F‑FDG‑PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 2005;90:105‑12.

12. Dehdasti F, Mortimer JE, Siegel BA, Griffeth et al. Positron tomographic assessment of estrogen receptors in breast cancer : comparison with 18F-FDG-PET and in vitro receptor assays. J Nucl Med 1995; 36: 1766-74

13. Mintun MA, Welch MJ, Siegel BA, Mathias CJ et al. Breast Cancer : PET imaging of estrogen receptors. Radiology 1988;169 : 45-8

14. Mc Guire AH, Dehdasti F, Seigel BA, Lyss AP et al. Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med 1991;32: 1526-31

15. Peterson LM, Mankoff DA, Lawton T, Yagle K et al. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J Nucl Med 2008; 49 : 367-74

16. Mortimer JE, Dehdasti F, Siegel BA, Katzenellenbogen JA et al. Positron emission tomography with 2-[18F] Fluoro-2-deoxy-D-glucose and 16 alpha-[18F] fluoro-17 beta estradiol in breast cancer : Correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 1996; 2 : 933-9

17. Chae SY, Kim SB, Ahn SH, et al. A randomized feasibility study of 18F- fluoroestradiol positron emission tomography to predict pathological response to neoadjuvant systemic therapy in estrogen receptor-rich postmenopausal breast cancer. J Nucl Med. 2017;58: 563-68

18. Yang Z, Sun Y, Xue J et al. Can positron emission tomography/computed tomography with dual tracers fluorine-18 fluoroestradiol and fluorodeoxyglucose predict neoadjuvant chemotherapy response of breast cancer? A pilot study. PLoS One 2013; 8 :e78192

19. Gupta M, Datta A, Choudhury PS, et al. Can 18F-Fluoroestradiol Positron Emission Tomography Become a New Imaging Standard in the Estrogen Receptor‑positive Breast Cancer Patient: A Prospective Comparative Study with 18F‑Fluorodeoxyglucose Positron Emission Tomography? World J Nucl Med 2017;16:133-9.

20. Choudhury PS. Developing a personalized treatment model based on molecular biomarkers and imaging in breast cancer: Has the time come? Indian J Nucl Med 2016;31:165.

Most read articles by the same author(s)

Obs.: This plugin requires at least one statistics/report plugin to be enabled. If your statistics plugins provide more than one metric then please also select a main metric on the admin's site settings page and/or on the journal manager's settings pages.